Table 4.
Responses in the three arms of the rituximab versus “watch-and-wait” study
| Time of response evaluation | 7 months | 13 months | 25 months |
|---|---|---|---|
|
Arm A (W&W) |
|
|
|
| + CRu |
3 (2%) |
6 (3%) |
5 (4%) |
| PR |
6 (3%) |
7 (4%) |
5 (4%) |
| ORR |
9 (5%) |
13 (7%) |
10 (8%) |
|
Arm B (Rx4) |
|
|
|
| CR + CRu |
35 (43%) |
36 (44%) |
30 (40%) |
| PR |
25 (30%) |
22 (27%) |
10 (13%) |
| ORR |
60 (73%) |
58 (71%) |
40 (53%) |
|
Arm C (Rx4RM) |
|
|
|
| CR + CRu |
100 (54%) |
122 (67%) |
98 (70%) |
| PR |
61 (33%) |
36 (20%) |
12 (9%) |
| ORR |
161 (87%) |
158 (87%) |
110 (79%) |
| p value (Arm B vs Arm C) | p = 0.0216 | p = 0.0077 | p < 0.0001 |
W&W: watch and wait; Rx4: rituximab four weekly doses; Rx4 + RM: rituximab four weekly doses plus rituximab maintenance; CR: complete response; CRu: undetermined complete response; PR: partial response; ORR: overall response rate.